Table I.
Clinical characteristics of patients with axial SpA
| Parameter | Patients with axial SpA (n = 49) |
|---|---|
| Age [years]* | 40.6 ±13 (24-75) |
| Gender | M 35, F 14 |
| aSpA duration [months] * | 59.6 ±71.5 (1- 260) |
| Age of aSpA diagnosis [years]* | 35 ±11.2 (17-65) |
| Age at the onset of aSpA* | 29 ±10.7 (12-58) |
| Delay of diagnosis [years]* | 6.5 ±6.9 (0-30) |
| ESR [mm/h] * | 30 ±24 (2-102) |
| CRP [mg/dl] * | 24.6 ±36 (0.5-201) |
| BASDAI * | 4.8 ±2.6 (0.3-9.6) |
| VAS back pain [mm] * | 48 ±30 (1-98) |
| BASFI * | 4.9 ±2.7 (0.1-9.9) |
| ASDAS - CRP * | 3.0 ±1.2 (0.6-5.7) |
| Disease activity # | |
| ASDAS < 2.1 | 8 (16%) |
| ASDAS > 2.1 | 41 (84%) |
| HLA B27 positive (%) | 92% |
*
Results presented as: mean ± SD (range)
#
Results presented as: number (percentage)
n – number of patients; M – males; F – females; ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; BASDAI – Bath Ankylosing Spondylitis Disease Activity Index; VAS – visual analogue scale; BASFI – Bath Ankylosing Spondylitis Functional Index; ASDAS – Ankylosing Spondylitis Disease Activity Score; HLA-B27 – human leukocyte antigen B27; aSpA – axial SpA